Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas.
In the evaluation of retroperitoneal masses, the practicing pathologist faces a dilemma when making a diagnosis based on histology given the often overlapping morphologic appearances of the adrenocortical carcinoma, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). CD10 is expressed in a membranous fashion in the vast majority of clear cell RCCs; therefore, it is widely used for distinction from its mimics. However, its expression is not well-investigated in adrenal cortical tumors. We examined CD10 expression in 47 surgically resected adrenocortical tumors (26 adenomas and 21 carcinomas) and compared with 20 clear cell RCCs and 25 HCCs. Twenty HCCs (80%), 18 RCCs (90%), 11 adrenocortical carcinomas (52%), and 18 adrenocortical adenomas (69%) were positive for CD10. HCCs were characterized by a canalicular staining, and clear cell RCCs exhibited membranous or mixed membranous-cytoplasmic staining. Adrenocortical tumors displayed mainly cytoplasmic staining. Four adrenocortical carcinomas and one adenoma also displayed the membranous staining pattern. Despite the relatively small number of samples, our preliminary results revealed that adrenocortical tumors may express CD10 (Clone: 56C6). The most important point from this paper is the fact that anti-CD10 expression has not been previously reported in adrenocortical carcinomas. This suggests that CD10 does not seem to be a useful marker for discriminating clear cell RCCs from adrenocortical tumors since CD10 expression does not rule out the possibility of adrenocortical tumors. This feature should be kept in mind when constructing an antibody panel for an epithelial tumor that involves the adrenal gland and kidney, especially in small biopsy specimens.
Mete
Ozgür
O
Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, Turkey. ozgurmete77@gmail.com
Kapran
Yersu
Y
Güllüoğlu
Mine G
MG
Kiliçaslan
Işin
I
Erbil
Yeşim
Y
Senyürek
Yasemin Giles
YG
Dizdaroğlu
Ferhunde
F
D000306:Adrenal Cortex Neoplasms / Q000175:diagnosis* / Q000276:immunology; D000328:Adult; D000951:Antigens, Neoplasm / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000276:immunology; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000276:immunology; D008113:Liver Neoplasms / Q000175:diagnosis / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000096:biosynthesis* / Q000276:immunology
D000951:Antigens, Neoplasm; D015260:Neprilysin
J Clin Endocrinol Metab. 2009 Jun;94(6):2178-83
19318454
Am J Surg Pathol. 2003 Mar;27(3):413-4
12604902
Am J Surg Pathol. 2000 Feb;24(2):203-10
10680888
Histopathology. 2004 Nov;45(5):452-9
15500648
Mol Cell Endocrinol. 2001 Jan 22;171(1-2):5-7
11165004
Histopathology. 2008 Jan;52(2):119-29
17825057
Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):347-52
16280664
Am J Surg Pathol. 2009 Feb;33(2):289-97
18852677
Am J Pathol. 1999 Jan;154(1):77-82
9916921
Am J Clin Pathol. 2000 Mar;113(3):374-82
10705818
Pathol Int. 2009 Jan;59(1):38-43
19121090
J Pediatr Hematol Oncol. 2010 Jan;32(1):2-3
20051779
Mod Pathol. 2003 Dec;16(12):1205-9
14681320
Pathology. 2009 Feb;41(2):191-3
19152193
Horm Res. 2008;70(5):294-9
18824868
Histopathology. 2004 Nov;45(5):460-7
15500649
J Clin Pathol. 2000 Mar;53(3):206-11
10823140